{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T01:52:32Z","timestamp":1785376352176,"version":"3.55.0"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00830","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T05:06:44Z","timestamp":1590556004000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Translating the Immunobiology of SBRT to Novel Therapeutic Combinations for Advanced Prostate Cancer"],"prefix":"10.3389","volume":"10","author":[{"given":"Victor R.","family":"Adorno Febles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Blacksburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2991\/jegh.k.191008.001","article-title":"Current cancer epidemiology","volume":"9","author":"Mattiuzzi","year":"2019","journal-title":"J Epidemiol Glob Health."},{"key":"B2","unstructured":"SEER Cancer Stat Facts: Prostate Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"JCO","DOI":"10.1200\/jco.18.00606","article-title":"Clinically localized prostate cancer: ASCO clinical practice guideline endorsement of an american urological association\/American society for radiation oncology\/Society of urologic oncology guideline","volume":"2018","author":"Bekelman","year":"2018","journal-title":"J Clin Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.juro.2017.11.095","article-title":"Clinically localized prostate cancer: aUA\/ASTRO\/SUO guideline","volume":"199","author":"Sanda","year":"2018","journal-title":"J Urol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 cHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/jco.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-Risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ijrobp.2017.07.021","article-title":"Conventional versus hypofractionated radiation therapy for localized or locally advanced prostate cancer: a Systematic review and meta-analysis along with therapeutic implications","volume":"99","author":"Datta","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B10","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1001\/jamaoncol.2018.6752","article-title":"Quality of life in patients with low-Risk prostate cancer treated with hypofractionated vs. conventional radiotherapy: a Phase 3 randomized clinical trial","volume":"5","author":"Bruner","year":"2019","journal-title":"JAMA Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.prro.2018.08.002","article-title":"Hypofractionated radiation therapy for localized prostate cancer: executive summary of an aSTRO, aSCO, and aUA evidence-Based guideline","volume":"8","author":"Morgan","year":"2018","journal-title":"Pract Radiat Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"12430","DOI":"10.1111\/ecc.12430","article-title":"Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer","volume":"27","author":"Zemplenyi","year":"2018","journal-title":"Eur J Cancer Care (Engl)."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/S0360-3016(98)00438-6","article-title":"Fractionation and protraction for radiotherapy of prostate carcinoma","volume":"43","author":"Brenner","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B14","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.ijrobp.2017.12.011","article-title":"Dose response and fractionation sensitivity of prostate cancer after external beam radiation therapy: a meta-analysis of randomized trials","volume":"100","author":"Vogelius","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.ijrobp.2006.10.050","article-title":"Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 gy in five fractions for localized disease: first clinical trial results","volume":"67","author":"Madsen","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B16","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.06.1912","article-title":"Stereotactic body radiation therapy for localized prostate cancer: a Systematic review and meta-Analysis of over 6,000 patients treated on prospective studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the hYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"The Lancet Oncology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/JU.0000000000000071","article-title":"Hypofractionated radiation therapy for localized prostate cancer: executive summary of an aSTRO, aSCO and aUA evidence-Based guideline","volume":"201","author":"Morgan","year":"2019","journal-title":"J Urol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.radonc.2018.02.029","article-title":"Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): a phase 2 randomized trial","volume":"127","author":"Quon","year":"2018","journal-title":"Radiother Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41391-019-0191-9","article-title":"Current use of stereotactic body radiation therapy for low and intermediate risk prostate cancer: a National cancer database analysis","volume":"23","author":"Malouff","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.prro.2017.11.008","article-title":"Stereotactic body radiation therapy (SBRT) for high-risk prostate cancer: where are we now?","volume":"8","author":"Gonzalez-Motta","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","article-title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the sTAMPEDE multi-arm, multi-stage platform protocol","volume":"29","author":"Sydes","year":"2018","journal-title":"Ann Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-Sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-Line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med."},{"key":"B26","first-page":"11","article-title":"Androgen deprivation therapy: indications, methods of utilization, side effects and their management","volume":"27","author":"Magee","year":"2020","journal-title":"Can J Urol."},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2019.11.010","article-title":"Androgen deprivation therapy and mental health: impact on depression and cognition","volume-title":"European urology focus.","author":"Izard","year":"2020"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-Sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet."},{"key":"B32","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-Directed therapy for oligometastatic prostate cancer recurrence: a Prospective, randomized, multicenter phase iI trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1200\/JCO.2020.38.6_suppl.10","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): five-year results of a randomized phase II trial","volume":"38","author":"Ost","year":"2020","journal-title":"J Clin Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.eururo.2018.06.004","article-title":"Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a Prospective clinical trial","volume":"74","author":"Siva","year":"2018","journal-title":"Eur Urol."},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs. stereotactic ablative radiation for oligometastatic prostate cancer: the oRIOLE phase 2 randomized clinical trial","volume-title":"JAMA Oncology.","author":"Phillips","year":"2020"},{"key":"B36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.critrevonc.2019.03.014","article-title":"Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: a position paper of italian association of radiotherapy and clinical oncology (AIRO)","volume":"138","author":"D'Angelillo","year":"2019","journal-title":"Crit Rev Oncol Hematol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/cancers9020013","article-title":"Immune modulation by androgen deprivation and radiation therapy: implications for prostate cancer immunotherapy","volume":"9","author":"Kalina","year":"2017","journal-title":"Cancers (Basel)."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","article-title":"The efficacy of radiotherapy relies upon induction of type i Interferon-Dependent innate and adaptive immunity","volume":"71","author":"Burnette","year":"2011","journal-title":"Cancer Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.4049\/jimmunol.181.5.3099","article-title":"Radiation-Induced cXCL16 release by breast cancer cells attracts effector t Cells","volume":"181","author":"Matsumura","year":"2008","journal-title":"J Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s40425-019-0704-z","article-title":"Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer","volume":"7","author":"Dudzinski","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1179064418761639","DOI":"10.1177\/1179064418761639","article-title":"The impact of radiation on the tumor microenvironment: effect of dose and fractionation schedules","volume":"11","author":"Arnold","year":"2018","journal-title":"Cancer Growth Metastasis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1182\/blood-2009-02-206870","article-title":"Therapeutic effects of ablative radiation on local tumor require cD8+ t cells: changing strategies for cancer treatment","volume":"114","author":"Lee","year":"2009","journal-title":"Blood."},{"key":"B43","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.4049\/jimmunol.174.12.7516","article-title":"Local radiation therapy of b16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor","volume":"174","author":"Lugade","year":"2005","journal-title":"J Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1158\/1078-0432.CCR-14-2824","article-title":"Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions","volume":"21","author":"Filatenkov","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.1158\/1078-0432.CCR-16-1673","article-title":"Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal t-cell populations when combined with pD-1 blockade","volume":"23","author":"Dovedi","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"558","DOI":"10.4049\/jimmunol.1200563","article-title":"Radiotherapy promotes tumor-specific effector cD8+ t cells via dendritic cell activation","volume":"189","author":"Gupta","year":"2012","journal-title":"J Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ijrobp.2018.01.071","article-title":"Targeting myeloid-derived suppressor cells and programmed death ligand 1 confers therapeutic advantage of ablative hypofractionated radiation therapy compared with conventional fractionated radiation therapy","volume":"101","author":"Lan","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e1395996","DOI":"10.1080\/2162402X.2017.1395996","article-title":"PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation","volume":"7","author":"Morisada","year":"2018","journal-title":"Oncoimmunology."},{"key":"B51","doi-asserted-by":"publisher","first-page":"6044","DOI":"10.1158\/0008-5472.CAN-19-0181","article-title":"A model of indirect cell death caused by tumor vascular damage after high-Dose radiotherapy","volume":"79","author":"Rodriguez-Barbeito","year":"2019","journal-title":"Cancer Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","article-title":"Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors","volume":"36","author":"Luke","year":"2018","journal-title":"J Clin Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to cTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nat Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.trecan.2016.05.002","article-title":"Radiotherapy: changing the game in immunotherapy","volume":"2","author":"Demaria","year":"2016","journal-title":"Trends Cancer."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen receptor signaling regulates dNA repair in prostate cancers","volume":"3","author":"Polkinghorn","year":"2013","journal-title":"Cancer Discov."},{"key":"B56","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1101\/cshperspect.a030627","article-title":"Immunotherapy for prostate cancer","volume":"9","author":"Venturini","year":"2019","journal-title":"Cold Spring Harb Perspect Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","article-title":"Randomized, double-Blind, phase iII trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-Naive castration-Resistant prostate cancer","volume":"35","author":"Beer","year":"2017","journal-title":"J Clin Oncol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers11010020","article-title":"The response of prostate cancer to androgen deprivation and irradiation due to immune modulation","volume":"11","author":"Wu","year":"2018","journal-title":"Cancers (Basel)."},{"key":"B60","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/bmt.2015.74","article-title":"Efficacy and safety of cDX-301, recombinant human flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers","volume":"50","author":"Anandasabapathy","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"B61","doi-asserted-by":"publisher","first-page":"4937","DOI":"10.1158\/1078-0432.CCR-17-1866","article-title":"Therapeutic immune modulation against solid cancers with intratumoral poly-ICLC: a Pilot trial","volume":"24","author":"Kyi","year":"2018","journal-title":"Clin Cancer Res."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00830\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T05:06:48Z","timestamp":1590556008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00830\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":61,"alternative-id":["10.3389\/fonc.2020.00830"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00830","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,27]]},"article-number":"830"}}